EXELON PATCH 5 Price

Overview

Welcome to Dwaey, specifically on EXELON PATCH 5 Patches/Transdermal page.
This medicine contains an important and useful components, as it consists of Rivastigmine (as hydrogen tartrate).
EXELON PATCH 5 is available in the market in concentration 9mg/Patch (4.6mg/24 Hr) and in the form of Patches/Transdermal.

NOVARTIS PHARMA AG is the producer of EXELON PATCH 5 and it is imported from SWITZERLAND, The most popular alternatives of EXELON PATCH 5 are listed downward .

Mode Of Action

Rivastigmine reversibly inhibits hydrolysis of acetylcholine by cholinesterases thus increasing acetylcholine present in the CNS. It is selective for the CNS and is used for the symptomatic treatment of dementia in Alzheimer's disease and idiopathic Parkinson's disease.

Indication

• Severe dementia in Alzheimer's disease
• Parkinson Dementia

Precaution

Patients with sick sinus syndrome or conduction defects, resp diseases. Cholinergic stimulation may increase gastric acid secretion. May exacerbate urinary obstruction and seizures. Pregnancy. Renal impairment, mild to moderate hepatic impairment. Monitor body wt. Asthma or obstructive pulmonary disease. May worsen extrapyramidal symptoms. Lactation. Lactation: Unknown if excreted in milk; not recommended

Side Effects

• >10% Nausea (PO 47%; patch 21%)
• Vomiting (PO 31%; patch 6-19%)
• Dizziness (PO 21%; patch 2-7%)
• Diarrhea (PO 19%; patch 6-10%)
• Headache (PO 17%; patch 3-4%)
• Anorexia (PO 17%; patch 3-9%)
• Abdominal pain (PO 13%; patch 2-4%) 1-10% Decreased weight (3-8%)
• Insomnia (PO 9%; patch 1-4%)
• Anxiety (PO 5%; patch 3%)
• Asthenia (PO 6%; patch 2-3%)
• Vertigo (2%)
• Fatigue (2%) Potentially Fatal: Serious GI reactions such as anorexia
• vomiting and weight loss.

Contra indication

Hypersensitivity to other carbamate derivatives. Severe hepatic impairment.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.